This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Acerus Pharmaceuticals 過去の業績
過去 基準チェック /06
主要情報
-22.8%
収益成長率
23.7%
EPS成長率
Pharmaceuticals 業界の成長 | 23.1% |
収益成長率 | -32.5% |
株主資本利益率 | n/a |
ネット・マージン | -924.3% |
前回の決算情報 | 30 Sep 2022 |
最近の業績更新
Recent updates
Auditors Have Doubts About Acerus Pharmaceuticals (TSE:ASP)
Mar 14Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12Acerus Pharmaceuticals' (TSE:ASP) Shareholders Are Down 88% On Their Shares
Jan 22The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30収支内訳
収支内訳
Acerus Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 22 | 3 | -28 | 20 | 7 |
30 Jun 22 | 3 | -29 | 20 | 7 |
31 Mar 22 | 3 | -28 | 22 | 5 |
31 Dec 21 | 2 | -34 | 22 | 5 |
30 Sep 21 | 2 | -32 | 20 | 4 |
30 Jun 21 | 2 | -34 | 21 | 3 |
31 Mar 21 | 1 | -33 | 20 | 3 |
31 Dec 20 | 1 | -24 | 18 | 3 |
30 Sep 20 | 1 | -21 | 17 | 2 |
30 Jun 20 | 1 | -19 | 14 | 2 |
31 Mar 20 | 2 | -16 | 12 | 2 |
31 Dec 19 | 4 | -16 | 10 | 3 |
30 Sep 19 | 5 | -17 | 9 | 3 |
30 Jun 19 | 7 | -16 | 8 | 3 |
31 Mar 19 | 8 | -19 | 9 | 3 |
31 Dec 18 | 7 | -19 | 9 | 2 |
30 Sep 18 | 8 | -16 | 8 | 3 |
30 Jun 18 | 7 | -16 | 8 | 2 |
31 Mar 18 | 7 | -11 | 7 | 2 |
31 Dec 17 | 7 | -9 | 7 | 2 |
30 Sep 17 | 6 | -7 | 6 | 2 |
30 Jun 17 | 6 | -5 | 6 | 2 |
31 Mar 17 | 15 | 3 | 6 | 2 |
31 Dec 16 | 24 | 11 | 5 | 2 |
30 Sep 16 | 31 | 3 | 5 | 2 |
30 Jun 16 | 32 | 5 | 5 | 2 |
31 Mar 16 | 24 | -3 | 5 | 3 |
質の高い収益: ASP is currently unprofitable.
利益率の向上: ASP is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ASP is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
成長の加速: Unable to compare ASP's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: ASP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.3%).
株主資本利益率
高いROE: ASP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.